Figure 2.
Overall survival from 8 and 24-month Landmarks by CR and MRD for GEP70 Low Risk patients. CR status at 8 months, A) and 24 months, B). Landmark analysis shows that optimum clinical benefit and most significant impact on OS is achieved only at the later time point (P=0.0005). Similarly, assessment of MRD status by NGS, C) post ASCT (at 8-month landmark), and D) during maintenance (24 months) depicts that MRD negativity had only prognostic value during maintenance (P=0.009).